^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Non Small Cell Lung Cancer
    Drug:MT-6402 (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Molecular Templates Press Release
    Title:

    Molecular Templates, Inc. Announces Fast Track Designation Granted by FDA for MT-6402

    Published date:
    11/18/2021
    Excerpt:
    Molecular Templates, Inc....today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for MT-6402 for the treatment of patients with advanced non-small cell lung cancer (NSCLC) expressing PD-L1.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

    Excerpt:
    ...Subject must be at least 18 years old and must have histologically confirmed, unresectable, locally advanced, or metastatic PD-L1-expressing solid cancer...
    Trial ID:
    NCT04795713